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Special Issue — Pharmacogenomics & personalized medicine, Journal of
Applied and Translational Genomics☆In 1892, Sir William Osler noted that “If it were not for the great
variability among individuals, medicine might as well be a science,
not an art” (Osler, W., The Principles & Practice of Medicine,
Appleton, NY, 1892). The observation is noteworthy not only for its
depth of perception but also for its place in time, namely before the
advent of penicillin and other important medicines that have pro-
duced cures and eliminated lethal diseases. Yet, despite that signiﬁ-
cant progress, the efﬁcacy of medicines prescribed for common
ailments hovers around 50–60%, and only 20% for cancer therapies.
Approximately 1.5 million preventable adverse drug events, esti-
mated to cost $4 billion, occur annually in the US (http://www.fda.
gov/Drugs/DrugSafety/ucm188760.htm). Prescription is always a
trade-off between beneﬁts to the patient and side-effects. The latter
can lead to non-compliance, which is particularly important in areas
with a high prevalence of communicable disease as this may lead to
the emergence of resistant microorganisms. Worldwide statistics do
not formally exist, though the societal burden is clearly formidable.
This is largely the result of the fact that the vast majority of medi-
cines are taken in dosages assumed to be safe and effective for all, ir-
respective of whether they are pediatric or adult patients. In other
words, for the past century physicians have known when they pre-
scribe that a particular medicine may not be safe and effective for
an individual patient, yet have had no alternative but to adopt a
trial and error approach to prescribing.
Only relatively recently has science been able to understand the
great variability in individuals' responses to drugs. In the 1950s scien-
tists ﬁrst discovered that genetic variation is associated with individual
variation in the activity of drug metabolizing enzymes. Variance in en-
zymatic activity was then thought both to demonstrate that inheritance
plays a role in drug response and also to explain adverse drug events.
Current knowledge is advancing these principles.
The ability to understand drug response at the molecular level is
enabling pharmacogenomics and personalized medicine to remedy
the ill effects of trial and error prescribing. Pharmacogenomics em-
ploys pharmacology and genomics to study how genes inﬂuence
an individual's response to pharmacotherapy. Personalized medi-
cine allows one to identify an individual's unique molecular charac-
teristics in order to more precisely diagnose disease and prescribe
speciﬁc treatments which are targeted to those characteristics,
thereby having a greater likelihood of being safe and efﬁcacious,
and thus improving outcomes and reducing adverse drug events.
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This Special Issue — ‘Pharmacogenomics & Personalized Medicine’
of Applied and Translational Genomics provides discrete examples
of current challenges and opportunities in the ﬁeld.
We begin with Fatima Barmania and Michael Pepper's article enti-
tled “C–C chemokine receptor type ﬁve (CCR5): An emerging target
for the control of HIV infection”. Understanding the molecular basis of
immune system dysregulation is pivotal to understanding precise
causes of a broad range of diseases and is crucial to identifying potential
treatment targets. HIV infection is a prime example of immune dysreg-
ulation and iswell known for having ravaged the lives of people in glob-
al proportions for decades. Arguably, the most clinically successful use
of pharmacogenetics (genotyping to predict drug response) is the
genotyping of HLA-B*5701 for hypersensitivity to antiretroviral drugs
used to treat HIV, such as abacavir. CCR5, the HIV co-receptor, has re-
cently emerged as a potential target in gene therapy aimed at “curing”
HIV/AIDS. Identifying targets for drug development represents a sub-
stantial advance in controlling failure of the immune system. So it is
ﬁtting to beginwith exciting new research that offers promise for devel-
oping a treatment targeted at the underlying cause of a disease that is
particularly devastating amongst the economically active in the devel-
oping world.
Promising drug targets require clinical trials to determine the
viability of a potential new therapeutic. Understanding the complex
genotype–phenotype interactions that inﬂuence drug response and
the detailed characterization of potential drug target genes is one
of the signiﬁcant challenges to advancing personalizedmedicine. De-
veloping precision medicines challenges conventional trial design
and execution, and with it the pharmaceutical industry's one size
ﬁts all blockbuster business model. Trials must be designed to iden-
tify not only population variations but also sub-population varia-
tions, requiring more advanced algorithms and appropriate study
designs to include genetic predictors and the multi-factorial nature
of drug response phenotypes. Nimita Limaye's “Pharmacogenomics,
theranostics and personalized medicine — The complexities of clini-
cal trials: Challenges in the developing world”, walks us through the
breadth and depth of the challenges to pharmacogenomic trial de-
sign and execution, demonstrating why these challenges are argu-
ably greatest in the developing world.
The development of precisionmedicine is evident in a broad range of
therapeutic modalities, including but not limited to stem cell technolo-
gies. Advances in stem cell technologies have generated hope for those
who but a few years ago had none. Both adult and pluripotent stem cells
offer the possibility of replacement of diseased cells and tissues to treat
a myriad of diseases, conditions and disabilities. Regrettably, seemingly
dramatic stem cell breakthroughs, particularly those that are not fullyaccess article under the CC BY-NC-ND license
2 Editorialvalidated, are offered by hucksters asmiracle cures and havemade their
way to areas lacking appropriate regulation and legislation to protect
the public from untoward practices, such as in Mexico and South Africa.
While hope exists that stem cells can one day cure such diseases,
conditions and disabilities, that day decidedly has not yet arrived.
Madelein Meissner-Roloff and Michael Pepper's article “Curbing stem
cell tourism in South Africa” examines the ethical concerns and scientif-
ic impact of a rush to establish the ﬁeld of stem cell therapy in the ab-
sence of governing legislation. The harm is particularly acute for a
country like South Africa because of its history of exceptional medicine
and its large population of individuals harboring cultural beliefs, rituals
and superstitious practices that make them arguably gullible targets.
Understanding how the absence of protective regulation and legislation
can permit unproven medicine to ﬂourish exposes not only illegal and
unethical practices but also a real danger to scientiﬁc progress. As the
authors poignantly argue, neglecting the proper procedure for estab-
lishing stem cell therapies is likely to result in a long delay in gaining
public support for the ﬁeld, thus hindering important work and further
delaying validated and clinically useful treatments. Global awareness of
this danger is necessary if society is to put into place the proper barriers
to ensure the legitimate advancement of the ﬁeld as well as the protec-
tion of vulnerable patients.
From there, we introduce the importance of sharing resources, build-
ing consensus and establishing standards in order to realize the promises
of genomic technologies for routine patient care. The path from bench to
bedside involves complexities associatedwith developing speciﬁcmolec-
ular diagnostic technologies for clinical use in a regulated environment.
The challenges are particularly acute given the rapidity with which new
molecular technologies are adopted in regulated clinical laboratories. As
NengChendiscusses inher article “Incorporating gene signature proﬁling
into routine molecular testing”, gene proﬁling and gene expression pro-
ﬁling illustrate how sophisticated molecular technologies are increasing-
ly an important part of disease management. She further discusses how
gene signature proﬁling will change the way molecular laboratories cur-
rently operate. Establishing data collection standards, analysis methods
andproper communicationbetween all stakeholders remains a challenge
for laboratories aspiring to keep pace with the technological advances
and deliver gene signature tests for routine clinical care.
We end this series with Gholson Lyon and Jeremy Segal's discussion
of stakeholder concerns in clinical sequencing and the promise of af-
fordable whole genome sequencing. They begin their article “Practical,
ethical and regulatory considerations for the evolving medical and re-
search genomics landscape” by discussing the importance of practical
as well as ethical and regulatory considerations as they impact person-
alized medicine's ability to become a standard of care and not a just
mere luxury for the rich or a “burdensome” cost center. They argue
that it is equally important to protect the well being of patients and re-
search subjects, to the extent that these categories are now functionallydifferent. Lyon and Segal discuss how and why it is imperative that se-
quencing be performed in appropriately regulated environments, such
as CLIA-certiﬁed laboratories cleared for high complexity testing. Next
generation sequencing is discussed for its ability to highlight the evolv-
ing overlap between patient and research subject regarding clinical care
and dissemination of genetic test results, including “incidental” results.
Whole genome sequencing represents an even greater degree of
research/clinical care overlap and highlights the increasing shift to pa-
tient centric research initiatives as well as care.
Further, new information technologies and social media continue to
alter privacy norms. Dissemination of genomic data, they claim, is be-
coming viewed as less unique and more like laboratory and imaging
data. This shift, they claim, is evident in the public's greater willingness
to share longitudinal phenotypic and genotypic data in publicly accessi-
ble online forums. For example, one can now register as an organ donor
on Facebook in much the same way as registering as a donor at the
motor vehicle registry department when renewing a driver's license.
Or one can register with PatientsLikeMe.com and post private medical
information about any clinical or research experience. The authors
argue for the need for a distributive model of information sharing,
such as these, which optimize cost and safety issues though greater re-
liance on work sharing designed to leverage speciﬁc strengths of geno-
mic centers and clinical interpretation teams. Such a model promises to
mitigate against many of the data sharing and other barriers preventing
the full realization of personalized medicine and to pave the way for
personalized medicine to be accessible to all.
We would like to express our deep gratitude to the authors and re-
viewers of this Special Issue.We hope that youwillﬁnd these articles in-
structive and thought provoking.
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